Search results
HI-Bio to Present at the 61st European Renal Association (ERA) Congress
FOX 5 San Diego· 4 hours agoPresentations will include data from the Phase 2 IGNAZ trial of felzartamab in patients with IgA nephropathy (IgAN) and a late-breaking oral presentation of complete Phase 2 data from the investigator-sponsored ...
Nuvation Bio (NYSE:NUVB) Shares Gap Up to $2.88
ETF DAILY NEWS· 9 hours agoShares of Nuvation Bio Inc. (NYSE:NUVB – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $2.88, but opened at $3.27. Nuvation ...
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
Motley Fool via Yahoo Finance· 7 hours agoFor most stocks, a 25% cut in an analyst's target price following an earnings release would send...
Nuvation Bio (NYSE:NUVB) Rating Increased to Buy at Jefferies Financial Group
ETF DAILY NEWS· 12 hours agoNuvation Bio (NYSE:NUVB – Get Free Report) was upgraded by equities research analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a research report ...
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Rating of “Buy” by Analysts
ETF DAILY NEWS· 13 hours agoCabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) has received a consensus rating of “Buy” from the nine analysts that are covering the stock, MarketBeat.com reports. CABA ...
IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line...
Morningstar· 7 hours agoSHANGHAI and NANJING, China and SAN JOSE, Calif., March 29, 2024 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and ...
Gossamer Bio (NASDAQ:GOSS) Receives Overweight Rating from Piper Sandler
ETF DAILY NEWS· 13 hours agoGossamer Bio (NASDAQ:GOSS – Get Free Report)‘s stock had its “overweight” rating restated by analysts at Piper Sandler in a research note issued on Wednesday, Benzinga reports ...
Maverix Medical Acquires Cirrus Bio With Plans To Develop Lung Cancer Diagnostics
GenomeWeb News· 2 hours agoMaverix Medical said Friday that it has closed its acquisition of Cirrus Bio, which it is incorporating into a new diagnostics arm, Maverix Dx, with plans to bring to market ...
Q1 2024 EPS Estimates for bluebird bio, Inc. Cut by Analyst (NASDAQ:BLUE)
ETF DAILY NEWS· 15 hours agoLeerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($0.29) per share for the quarter, down from their previous forecast of ($0.24). The ...
...INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with...
Morningstar· 18 hours agoSAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the bluebird bio class action lawsuit seeks to represent purchasers or acquirers ...